NCT02505984View on ClinicalTrials.gov

Preventing Postpartum Depression With Intranasal Oxytocin

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

May 31, 2023

Study Completion Date

May 31, 2023

Conditions
Depression, PostpartumAnxiety
Interventions
DRUG

Oxytocin

Study participants will be randomized to a placebo or drug group.

DRUG

Placebo

Study participants will be randomized to a placebo or drug group.

Trial Locations (1)

02114

Massachusetts General Hosptial, Boston

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Massachusetts General Hospital

OTHER

NCT02505984 - Preventing Postpartum Depression With Intranasal Oxytocin | Biotech Hunter | Biotech Hunter